Inclusion Criteria:
* Severe aortic valve stenosis diagnosed according to criteria established in current guidelines.
* Intermediate or higher surgical risk, defined as a Society of Thoracic Surgeons (STS) score ≥4%.
* Indication for transcatheter aortic valve implantation (TAVI).
* Willing and able to participate in the study and provide written informed consent.
Exclusion Criteria:
* Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., indication for a mechanical heart valve).
* Known hypersensitivity or contraindication to aspirin, clopidogrel, heparin, nitinol (titanium or nickel), or contrast media that cannot be adequately managed with premedication. This includes heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITTS).
* Blood dyscrasias, including leukopenia (white blood cell count \<1,000/mm³), thrombocytopenia (platelet count \<100,000 cells/mm³), history of coagulopathy, or hypercoagulable states.
* Active infection, including endocarditis.
* Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or requirement for mechanical hemodynamic support.
* Stroke or transient ischemic attack (TIA) within 2 months prior to the index procedure.
* History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy.
* Estimated life expectancy of less than 24 months.
* Other medical, social, or psychological conditions that, in the investigator's opinion, may prevent the participant from providing informed consent or adequately complying with the study protocol.
* Pre-existing prosthetic heart valve, either biological or mechanical, in the aortic position.
* Concomitant severe mitral or tricuspid valve disease.
* Hypertrophic obstructive cardiomyopathy.
* Successful percutaneous coronary intervention (PCI) performed within 48 hours prior to TAVI.
* Femoral artery diameter \<5.5 mm for SAFESYNC 20-24 mm, \<6.0 mm for SAFESYNC 26-28 mm, or \<6.5 mm for SAFESYNC 30 mm.
* High risk of aortic annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract.
* High risk of coronary obstruction, defined by computed tomography angiography as coronary ostial height \<10 mm with narrow sinuses of Valsalva (SOV), with a mean SOV diameter \<3 mm greater than the bioprosthetic valve size.
* Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%.
* Severe chronic kidney disease, defined as glomerular filtration rate (GFR) \<30 mL/min/1.73 m².
